| |
| |
|
| Insider
Information: |
Bancroft Charles A |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
168,937 |
|
|
Indirect Shares
|
300,000 |
|
|
| Direct
Value |
$6,749,969 |
|
|
|
Indirect Value
|
$13,455,000 |
|
|
| Total
Shares |
468,937 |
|
|
| Total
Value |
$20,204,969 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bristol-Myers Squibb Co |
BMY |
EVP, Head of Integration |
2020-03-10 |
137,534 |
2020-03-10 |
300,000 |
Premium* |
|
|
Colgate Palmolive Co |
CL |
Director |
2018-05-14 |
5,455 |
2017-05-15 |
0 |
Premium* |
|
|
Kodiak Sciences Inc. |
KOD |
Director |
2020-04-02 |
25,948 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KOD |
Kodiak Sciences Inc. |
Director |
– • – |
2020-04-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,948 |
|
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
• – – |
2020-03-10 |
4 |
D |
$57.93 |
$1,930,286 |
D/D |
(33,321) |
137,534 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
• – – |
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,075 |
158,045 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
• – – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
71,868 |
153,637 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
• – – |
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(397) |
106,408 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
• – – |
2020-03-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
300,000 |
300,000 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Head of Integration |
• – – |
2020-03-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
300,000 |
92,309 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$1,254,070 |
D/D |
(24,403) |
395,994 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,735) |
376,895 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,255 |
411,547 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2019-02-28 |
4 |
D |
$51.93 |
$1,548,189 |
D/D |
(29,813) |
362,877 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2019-02-28 |
4 |
OE |
$17.51 |
$925,999 |
D/D |
52,884 |
392,690 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-12-02 |
4/A |
D |
$53.46 |
$145,197 |
D/D |
(2,716) |
339,806 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-12-02 |
4/A |
OE |
$0.00 |
$0 |
D/D |
6,401 |
342,522 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-12-02 |
4 |
D |
$53.46 |
$145,197 |
D/D |
(2,716) |
203,401 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,401 |
206,117 |
0 |
- |
|
| CL |
Colgate Palmolive Co |
Director |
• • – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,901 |
5,455 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
3,469 |
302,298 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
91,318 |
363,739 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-03-10 |
4 |
D |
$67.92 |
$2,731,131 |
D/D |
(40,211) |
336,121 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-02-23 |
4 |
D |
$66.68 |
$1,387,144 |
D/D |
(20,803) |
281,545 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2018-02-23 |
4 |
OE |
$22.14 |
$829,364 |
D/D |
37,460 |
302,348 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2017-12-02 |
4 |
D |
$62.47 |
$180,039 |
D/D |
(2,882) |
264,888 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & Chief Financial Officer |
• – – |
2017-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,401 |
267,770 |
0 |
- |
|
| CL |
Colgate Palmolive Co |
Director |
• • – |
2017-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,512 |
2,512 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
